2.08
price down icon1.89%   -0.04
 
loading
Schlusskurs vom Vortag:
$2.12
Offen:
$2.12
24-Stunden-Volumen:
28,679
Relative Volume:
0.02
Marktkapitalisierung:
$18.13M
Einnahmen:
$93.76M
Nettoeinkommen (Verlust:
$-13.68M
KGV:
-0.7909
EPS:
-2.63
Netto-Cashflow:
$8.77M
1W Leistung:
+4.00%
1M Leistung:
+5.05%
6M Leistung:
+36.84%
1J Leistung:
-27.27%
1-Tages-Spanne:
Value
$2.06
$2.16
1-Wochen-Bereich:
Value
$1.96
$2.17
52-Wochen-Spanne:
Value
$0.95
$2.96

Aytu Biopharma Inc Stock (AYTU) Company Profile

Name
Firmenname
Aytu Biopharma Inc
Name
Telefon
(720) 437-6580
Name
Adresse
7900 E. UNION AVENUE, DENVER
Name
Mitarbeiter
102
Name
Twitter
@aytubioscience
Name
Nächster Verdiensttermin
2024-12-13
Name
Neueste SEC-Einreichungen
Name
AYTU's Discussions on Twitter

Vergleichen Sie AYTU mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - Specialty & Generic icon
AYTU
Aytu Biopharma Inc
2.08 18.13M 93.76M -13.68M 8.77M -2.63
Drug Manufacturers - Specialty & Generic icon
RGC
Regencell Bioscience Holdings Ltd
17.04 303.95B 0 -5.87M -767.30K -0.45
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
156.53 74.39B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
10.39 48.97B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
15.12 47.39B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.77 20.17B 16.54B -1.64B 749.00M -1.45

Aytu Biopharma Inc Stock (AYTU) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2021-03-30 Eingeleitet Cantor Fitzgerald Overweight
2020-05-29 Eingeleitet H.C. Wainwright Buy

Aytu Biopharma Inc Aktie (AYTU) Neueste Nachrichten

pulisher
Jun 15, 2025

Aytu BioPharma, Inc. (NASDAQ:AYTU) Sees Significant Decline in Short Interest - Defense World

Jun 15, 2025
pulisher
Jun 14, 2025

Insider Spends US$100k Buying More Shares In Aytu BioPharma - simplywall.st

Jun 14, 2025
pulisher
Jun 14, 2025

CEO & Director of Aytu BioPharma Joshua Disbrow Buys 77% More Shares - Yahoo Finance

Jun 14, 2025
pulisher
Jun 11, 2025

Transcript : Aytu BioPharma, Inc.Special Call - MarketScreener

Jun 11, 2025
pulisher
Jun 10, 2025

Insider Buying: Jarrett Disbrow Acquires Shares of Aytu BioPharm - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Insider Buying: Jarrett Disbrow Acquires Shares of Aytu BioPharma Inc (AYTU) - GuruFocus

Jun 10, 2025
pulisher
Jun 10, 2025

Aytu Biopharma chief business officer buys $24,999 in stock By Investing.com - Investing.com South Africa

Jun 10, 2025
pulisher
Jun 10, 2025

Aytu Biopharma chief business officer buys $24,999 in stock - Investing.com Australia

Jun 10, 2025
pulisher
Jun 10, 2025

Aytu Biopharma CEO Joshua Disbrow acquires $99,999 in stock By Investing.com - Investing.com Canada

Jun 10, 2025
pulisher
Jun 10, 2025

Aytu Biopharma CEO Joshua Disbrow acquires $99,999 in stock - Investing.com Australia

Jun 10, 2025
pulisher
Jun 10, 2025

AYTU BIOPHARMA Executives Increase Stake in Company - TradingView

Jun 10, 2025
pulisher
Jun 09, 2025

Aytu BioPharma Announces Closing of Upsized At the Market Public - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Aytu BioPharma Announces Closing of Upsized At the Market Public Offering of Common Stock with Full Exercise of Overallotment and Conference Call to Discuss First-in-Class Antidepressant EXXUA(TM) Opportunity and Commercialization Plan - ACCESS Newswire

Jun 09, 2025
pulisher
Jun 09, 2025

Breakthrough: First Depression Drug Without Sexual Side Effects Gets $16.6M Backing for Q4 Launch - Stock Titan

Jun 09, 2025
pulisher
Jun 09, 2025

Aytu BioPharma to commercialise Exxua for MDD in the US - Yahoo Finance

Jun 09, 2025
pulisher
Jun 07, 2025

Aytu BioPharma (AYTU) Announces Upsized Public Offering to Fund - GuruFocus

Jun 07, 2025
pulisher
Jun 06, 2025

Aytu BioPharma secures exclusive rights to new MDD drug By Investing.com - Investing.com South Africa

Jun 06, 2025
pulisher
Jun 06, 2025

Aytu BioPharma Announces Exclusive Agreement with Fabre-Kramer P - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

AYTU Increases Common Stock Offering to 9.6 Million Shares | AYT - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

AYTU Increases Common Stock Offering to 9.6 Million Shares | AYTU Stock News - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Aytu BioPharma (AYTU) Secures Exclusive Deal for U.S. Launch of - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Aytu BioPharma secures exclusive rights to new MDD drug - Investing.com

Jun 06, 2025
pulisher
Jun 06, 2025

Aytu BioPharma Announces At the Market Pricing of $14.4 Million Upsized Public Offering of Common Stock | AYTU Stock News - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Aytu BioPharma (AYTU) Secures Exclusive Deal for U.S. Launch of Exxua Tablets | AYTU Stock News - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

AytuBioPharma (AYTU) Secures Exclusive Rights to Commercialize EXXUA in the U.S. | AYTU Stock News - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Aytu BioPharma Announces Exclusive Agreement with Fabre-Kramer Pharmaceuticals to Commercialize First-in-Class Antidepressant EXXUA(TM) (gepirone) Extended-Release Tablets in the United States | AYTU - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Aytu BioPharma Announces At the Market Pricing of $14.4 Million Upsized Public Offering of Common Stock - ACCESS Newswire

Jun 06, 2025
pulisher
Jun 06, 2025

Aytu BioPharma Secures $14.4M Financing: Major Funds Back EXXUA Depression Drug Commercialization - Stock Titan

Jun 06, 2025
pulisher
Jun 06, 2025

New Antidepressant EXXUA Enters $22B Market Without Sexual Side Effects | AYTU Stock News - Stock Titan

Jun 06, 2025
pulisher
Jun 02, 2025

AYTU: Lake Street Takes Role as Sole Book-Running Manager | AYTU Stock News - GuruFocus

Jun 02, 2025
pulisher
May 29, 2025

Aytu BioPharma, Inc. (NASDAQ:AYTU) Sees Significant Growth in Short Interest - Defense World

May 29, 2025
pulisher
May 18, 2025

Aytu signals ongoing portfolio expansion opportunities as Q3 2025 revenue surges 32% - MSN

May 18, 2025
pulisher
May 18, 2025

Aytu BioPharma Ranked Number 178 Fastest-Growing Company in North America on the 2021 Deloitte Technology Fast 500(TM) - ACCESS Newswire

May 18, 2025
pulisher
May 16, 2025

Aytu BioPharma (AYTU) Reports Significant Revenue Growth in Q3 2 - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Aytu BioPharma, Inc. (NASDAQ:AYTU) Q3 2025 Earnings Call Transcript - Insider Monkey

May 16, 2025
pulisher
May 16, 2025

Earnings call transcript: Aytu BioPharma Q2 2025 sees revenue dip, strategic shifts - MSN

May 16, 2025
pulisher
May 16, 2025

Aytu BioPharma Third Quarter 2025 Earnings: Beats Expectations - Yahoo Finance

May 16, 2025
pulisher
May 15, 2025

Aytu BioPharma Reports Fiscal 2025 Third Quarter Operational and Financial Results | AYTU Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Aytu BioPharma Inc (AYTU) Q3 2025 Earnings: EPS of $0.21 Beats E - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Why Boot Barn Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket - Benzinga

May 15, 2025
pulisher
May 15, 2025

Aytu BioPharma Inc (AYTU) Q3 2025 Earnings Call Highlights: Stro - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Aytu BioPharma Reports Strong Q3 2025 Earnings - TipRanks

May 15, 2025
pulisher
May 14, 2025

Aytu Biopharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 14, 2025
pulisher
May 14, 2025

Aytu BioPharma (AYTU) Reports Strong Q3 Earnings Beat - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Earnings call transcript: Aytu BioPharma sees Q3 revenue surge, stock jumps - Investing.com India

May 14, 2025
pulisher
May 14, 2025

Aytu BioPharma Reports Fiscal 2025 Third Quarter Results - TradingView

May 14, 2025
pulisher
May 14, 2025

Transcript : Aytu BioPharma, Inc., Q3 2025 Earnings Call, May 14, 2025 - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

Aytu BioPharma Reports Fiscal 2025 Third Quarter Operational and Financial Results - ACCESS Newswire

May 14, 2025
pulisher
May 14, 2025

We Think Some Shareholders May Hesitate To Increase Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO Compensation - simplywall.st

May 14, 2025
pulisher
May 13, 2025

Aytu BioPharma to Report Fiscal 2025 Third Quarter Operational a - GuruFocus

May 13, 2025
pulisher
May 09, 2025

Aytu BioPharma to Participate in the Lytham Partners Summer 2022 Investor Conference - ACCESS Newswire

May 09, 2025

Finanzdaten der Aytu Biopharma Inc-Aktie (AYTU)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Aytu Biopharma Inc-Aktie (AYTU) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Disbrow Joshua R.
Chief Executive Officer
Jun 09 '25
Buy
1.50
66,666
99,999
153,257
Disbrow Joshua R.
Chief Executive Officer
Feb 28 '25
Buy
1.30
15,000
19,500
86,591
$14.24
price down icon 0.28%
$9.09
price down icon 0.44%
$126.00
price down icon 0.61%
$283.17
price up icon 0.09%
drug_manufacturers_specialty_generic RDY
$15.15
price down icon 1.32%
$16.47
price down icon 2.82%
Kapitalisierung:     |  Volumen (24h):